HIA Sainte Anne — Clinical Trial Site

64 Registered trials

21 Currently recruiting

Organisation

HIA Sainte Anne

Location

Toulon Cedex 9, France

Identifier

ORG-100045575

Address

2 Boulevard Sainte Anne, Bp 600, 83800, France

Departments

#1213: Neurology
#2057: Service Dermatologie et vénéréologie
#40285: Service de dermatologie
1815 :Rhumatologie
1815: Internal Medicine
2308:Service de pneumologie
2406:Service de Pneumologie
40887: Service de Dermatologie
Anesthesiology and intensive care
Department of Oncology-Pneumology
Dermatologie Venereologie
Dermatology
Dermatology Department
gastro enterology
Gastroenterolgy
gastroenterology
Hématologie
hépato gastro enterology
Hepatogastroenterology
HIA Sainte Anne, Respiratory departement
Internal Medicine
Maladies Respiratoires
Médecine Interne
medical oncology
n/a
NA
Neurologie
Neurology
Neuroradiologie Interventionnelle
Onco-Hématologie
Oncologie
Oncologie-Hématologie
Oncology - Hematology
Pathologie Respiratoire
Pneumologie
Pneumology
Pneumology department
Respiratory Department
Satellite site Pneumology Department
Service de Dermatologie
Service de médecine interne
Service de Pneumologie
Service pneumologie
URC - HIA SAINTE ANNE

Clinical trials at this site (64)

Search interface

Study of Neoadjuvant and Adjuvant Treatment in Patients with Resectable Non-small Cell Lung Cancer Recruiting

2023-508852-21-00 Resectable, Early-stage (II to IIIB) Non-small Cell Lun 4 2022-06-10
A2B-trial Antibioprophylaxis for excision-graft surgery in burn patient : a multicenter randomized double-bling study Recruiting

2024-514349-13-00 Excision-autograft surgery in burn patient 5 2020-10-11
Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide versus Durvalumab, Carboplatin, and Etoposide in First-Line ES-SCLC (DeLL… Ended

2024-520050-38-00 Extensive stage small cell lung cancer (ES-SCLC). 5 2025-09-18
A multi-center, open-label extension study of subcutaneous secukinumab to evaluate the long-term safety and tolerability in polymyalgia rheu… Ended

2023-508077-85-00 Polymyalgia Rheumatica 5 2024-11-19
ISASOCUT-IFM2022-05-Multicenter phase 2 study of subcutaneous isatuximab plus bortezomib, lenalidomide and dexamethasone in the treatment of… Ended

2024-517099-39-00 Newly diagnosed transplant ineligible multiple myeloma 4 2024-11-18
PRODIGE 49 - OSCAR: Systemic oxaliplatin or in intra-arterial chemotherapy combined with LV5FU2 ± Irinotecan, and targeted therapy, in first… Ended

2024-518553-41-00 colon cancer and rectal with liver metastasis 5 2024-11-08
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Patients with previously treated KRAS G12C-positive… Ended

2024-510908-37-00 KRAS G12C-Positive Advanced or Metastatic Non-Small Cel 5 2024-08-28
Selective Treatment of Oral Povorcitinib in Hidradenitis Suppurativa Long-Term Extension Study (STOP-HS LTE) Ended

2023-507204-31-00 Hidradenitis Suppurativa 5 2024-07-26
Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis Ended

2023-508235-31-00 Atopic Dermatitis 5 2024-06-17
52 weeks double-blind, double-dummy, randomized placebo-controlled trial to evaluate safety, efficacy and tolerability of remibrutinib in co… Ended

2022-502161-19-00 Chronic Spontaneous Urticaria 5 2024-03-12
PRODIGE 85 (FFCD 1804) – KANALRAD Prospective randomized phase III study evaluating induction chemotherapy (modified DCF 4 cycles) followed… Ended

2023-505972-32-00 locally advanced anal squamous cell carcinoma 5 2024-02-26
Patient Preference Study of SC Pembrolizumab versus IV Pembrolizumab with hyaluronidase (MK-3475A) in multiple cancer types Ended

2023-506017-22-00 Melanoma, Renal Cell Carcinoma, Non-small cell lung can 4 2024-02-16
IFCT-2201 ADAPTABLE A study evaluating the combination of paclitaxel-bevacizumab ± atezolizumab in patients with advanced lung cancer progre… Ended

2022-502103-30-00 advanced non-squamous non-small cell lung cancer 4 2023-04-25
Dupilumab step-down strategy to maintain remission in adult and adolescents patients with atopic dermatitis: a non-inferiority randomized tr… Ended

2022-501179-23-00 atopic dermatitis 6 2023-03-08
A Study of Dato-DXd in Combination With Durvalumab and Carboplatin for First-line Treatment of Advanced NSCLC Without Actionable Genomic Alt… Ended

2023-505993-14-00 Non-Small Cell Lung Cancer (NSCLC) 5 2023-01-05
Study of ceralasertib plus durvalumab versus docetaxel for patients with advanced or metastatic non-small cell lung cancer Ended

2023-509429-37-00 Advanced or Metastatic Non-Small Cell Lung Cancer 5 2022-10-03
IFCT-2101 MASTERPROTOCOL ALK : Study of safety and efficacy of brigatinib and carboplatin-pemetrexed combination therapy or brigatinib monot… Ended

2023-510387-13-00 advanced ALK-positive non-small cell lung cancer 4 2022-05-18
Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treat… Ended

2023-509372-41-00 Multiple Sclerosis 5 2022-01-30
Study comparing the standard administration of immunotherapy (IO) versus the same agent administered each three months in patients with loca… Ended

2024-513707-14-00 Only patients with oncologic locally advanced or metast 5 2022-01-14
IFM2020-05-BENEFIT-Multicenter Open label Phase 3 study of Isatuximab plus Lenalidomide and Dexamethasone with/without Bortezomib in the Tre… Ended

2024-517215-67-00 Newly diagnosed Non-Frail transplant Ineligible Multipl 5 2021-06-11
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed … Ended

2023-504959-27-00 Participants with Limited Stage-Small Cell Lung Cancer, 5 2020-12-09
A Randomized Prospective Trial of Adjuvant Chemotherapy in Patients with Completely Resected Stage I or IIA Non-Squamous Non-Small Cell Lung… Ended

2024-511185-37-00 Completely resected stage I or IIA non-squamous non-sma 6 2020-11-03
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell… Ended

2023-503591-25-00 Non-small cell lung cancer 5 2020-06-09
MEthotrexate versus TOcilizumab for treatment of GIant cell Arteritis: a multicenter, randomized, controlled trial Ended

2024-512269-14-00 GIant cell Arteritis 5 2020-01-27